Synaptic vesicle cycling is the fundamental process by which neurotransmitters are released from presynaptic terminals. This pathway encompasses vesicle mobilization, docking, fusion, release, and recycling. Dysregulation of these processes has emerged as a critical mechanism in neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). [@selkoe2002]
Synaptic vesicles exist in three main pools within the presynaptic terminal: [@bellucci2020]
In AD, synaptic dysfunction occurs early and correlates with cognitive decline: [@sheng2012]
Synaptic vesicle dysfunction is central to PD pathogenesis: [@burr2015]
| Protein | Gene | Function | Neurodegeneration Link | [@mukherjee2020]
|---------|------|----------|----------------------| [@sdhof2013]
| Synaptophysin | SYP | Major vesicle protein | Reduced in AD | [@gillingwater2013]
| Synaptotagmin-1 | SYT1 | Ca²⁺ sensor for release | Dysregulated in PD | [@kelley2018]
| Synaptobrevin-2 | VAMP2 | v-SNARE for fusion | Cleaved in tetanus |
| SNAP-25 | SNAP25 | t-SNARE | Reduced in AD |
| Syntaxin-1 | STX1 | t-SNARE | Target of toxins |
| VGLUT1 | SLC17A6 | Glutamate transport | Reduced in AD |
| VMAT2 | SLC18A2 | Dopamine transport | PD therapeutic target |
| Rab3A | RAB3A | Vesicle trafficking | Impaired in PD |
The SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor) complex is essential for synaptic vesicle fusion. In neurodegeneration, multiple components become impaired:
SNAP-25 (Synaptosomal-Associated Protein 25): This Q-SNARE protein shows reduced expression in both AD and PD brains. Studies demonstrate decreased SNAP-25 levels in the prefrontal cortex of AD patients and in the substantia nigra of PD patients. Post-mortem studies reveal that SNAP-25 cleavage by proteases creates fragments that may act as dominant-negative inhibitors of synaptic transmission. [@voronov2023]
Syntaxin-1: The t-SNARE syntaxin-1A interacts with both SNAP-25 and synaptotagmin to form the complete SNARE complex. Research shows reduced syntaxin-1 levels in AD hippocampus, particularly in regions associated with learning and memory. Syntaxin-1 may be directly targeted by amyloid-beta oligomers, disrupting the normal SNARE assembly process.
VAMP2 (Synaptobrevin-2): As the primary v-SNARE, VAMP2 mediates vesicle membrane fusion with the presynaptic plasma membrane. In PD, VAMP2 function is impaired by alpha-synuclein aggregation, which competitively binds to the SNARE complex and reduces its efficiency.
The proton gradient across the synaptic vesicle membrane, generated by V-ATPase, is critical for neurotransmitter loading and is disrupted in neurodegeneration: [@chen2024]
V-ATPase Dysfunction: Synaptic vesicles require V-ATPase activity to establish the electrochemical gradient necessary for neurotransmitter uptake. In AD models, V-ATPase subunits show reduced expression, leading to impaired proton pump function and decreased neurotransmitter loading capacity.
Impaired Neurotransmitter Loading: Reduced acidification leads to decreased uptake of neurotransmitters into synaptic vesicles. This affects glutamate, GABA, dopamine, and acetylcholine systems, contributing to the broad synaptic dysfunction observed in neurodegenerative diseases.
Rab proteins regulate synaptic vesicle trafficking at multiple stages: [@liu2024]
Rab3: This Rab protein is enriched on synaptic vesicles and regulates vesicle docking and priming. In PD models, Rab3A shows altered cycling kinetics, contributing to deficits in sustained neurotransmitter release during high-frequency firing.
Rab5: Involved in early endosome function and synaptic vesicle recycling. Rab5 dysregulation impairs the retrieval of synaptic vesicle components after exocytosis, leading to progressive depletion of the synaptic vesicle pool.
Rab11: Functions in vesicle recycling through the slow recycling pathway. Impaired Rab11 function contributes to defects in synaptic vesicle replenishment observed in neurodegenerative disease models.
Amyloid-beta (Aβ) oligomers directly impair synaptic vesicle cycling through multiple mechanisms: [@zhong2023]
Vesicle Pool Depletion: Aβ oligomers bind to presynaptic terminals and reduce the size of the readily releasable pool (RRP) of synaptic vesicles. This effect precedes visible synapse loss and correlates with early cognitive deficits in AD.
Calcium Buffering Impairment: Aβ disrupts presynaptic calcium handling by affecting calcium channels and buffers. This leads to altered activity-dependent modulation of synaptic strength and contributes to impaired synaptic plasticity.
Mitochondrial Energy Failure: Aβ accumulates in presynaptic mitochondria, reducing ATP production. Since synaptic vesicle cycling is ATP-intensive, energy deficits impair all stages from vesicle acidification to endocytosis.
Tau pathology affects synaptic function through both pre- and postsynaptic mechanisms: [@circelli2022]
Presynaptic Tau Accumulation: Hyperphosphorylated tau accumulates in presynaptic terminals in AD and tauopathies, disrupting synaptic vesicle organization and reducing the reserve pool of vesicles.
Impaired Vesicle Trafficking: Tau interferes with microtubule-based transport of synaptic vesicles along axons, reducing replenishment of synaptic vesicle pools during sustained activity.
Synaptic Mitochondria Targeting: Pathological tau localizes to synaptic mitochondria, impairing their function and reducing local ATP availability for synaptic vesicle cycling.
In AD, synaptic dysfunction occurs before visible neurodegeneration and correlates strongly with cognitive decline:
Aβ-Induced Presynaptic Impairment: Soluble Aβ oligomers bind to synaptic terminals and specifically target the SNARE complex. Experimental models show that Aβ treatment reduces SNARE protein levels and impairs Ca²⁺-triggered release.
Glutamatergic Synaptic Deficits: The excitatory glutamatergic system, particularly in the hippocampus, shows early impairments. VGLUT1 (vesicular glutamate transporter 1) expression is reduced in AD brains, leading to impaired glutamate release and disrupted excitatory signaling. [@zhang2024]
Cholinergic Dysfunction: Basal forebrain cholinergic neurons, which are critical for attention and memory, show particularly severe synaptic vesicle cycling impairments in AD, contributing to the characteristic memory deficits.
Dopaminergic terminals in the striatum show unique vulnerabilities in PD: [@yang2023]
Alpha-Synuclein Binding: Wild-type and mutant α-synuclein bind directly to synaptic vesicles, altering their distribution and function. This affects both the readily releasable pool and the reserve pool of vesicles.
VMAT2 Dysfunction: The vesicular monoamine transporter 2 (VMAT2) is responsible for packaging dopamine into synaptic vesicles. MPP+ and other PD toxins inhibit VMAT2 function, leading to cytosolic dopamine accumulation and oxidative stress.
Synchronous Release Deficits: Dopaminergic neurons exhibit low firing rates but require precise timing for signaling. Impaired synchronous release affects the fidelity of dopaminergic transmission in the striatum.
Motor neurons show specific patterns of synaptic dysfunction in ALS: [@calo2023]
Synaptic Vesicle Depletion: Motor nerve terminals show accelerated depletion of synaptic vesicles during repetitive firing, contributing to the characteristic muscle weakness.
Calcium Buffering Defects: Motor neurons rely heavily on calcium buffers like calbindin to handle high-frequency firing demands. Impaired buffering leads to calcium dysregulation and excitotoxicity.
Mitochondrial Dysfunction: Motor neurons have exceptionally high energy demands, making them particularly vulnerable to mitochondrial dysfunction that impairs synaptic vesicle cycling.
Tau-Dependent Vesicle Dysfunction: In tauopathies, presynaptic tau accumulation directly impairs vesicle cycling. Studies in tau transgenic models show reduced synaptic vesicle numbers and impaired release probability.
Impaired Synaptic Plasticity: Tau pathology affects both short-term and long-term synaptic plasticity. Defects in presynaptic vesicle cycling contribute to deficits in activity-dependent synaptic strengthening. [@martella2023]
Glutamate is the primary excitatory neurotransmitter in the brain, and its release is impaired in AD:
GABAergic inhibition is altered in neurodegeneration:
Dopamine release is specifically affected in PD:
The cholinergic system is particularly vulnerable in AD:
Synaptic vesicle cycling requires substantial ATP: [@hernandez2024]
Mitochondrial Calcium Handling: Presynaptic mitochondria buffer calcium during high-frequency activity. In neurodegeneration, impaired mitochondrial calcium handling reduces the capacity to support sustained vesicle cycling.
** glycolytic Support**: Recent research shows that synaptic terminals rely on glycolysis alongside oxidative phosphorylation. Glycolytic enzyme function is impaired in AD, reducing the flexibility of energy supply.
ATP Sensor Function: Synaptic vesicle proteins including V-ATPase and neurotransmitter transporters are directly regulated by ATP levels. Energy deficits therefore have direct functional consequences beyond general cellular health.
SNARE Complex Stabilizers: Compounds that stabilize the SNARE complex and protect against proteolytic cleavage are in development. Peptide-based approaches aiming to prevent SNAP-25 fragmentation show promise in preclinical models.
Calcium Channel Modulators: P/Q-type and N-type calcium channel modulators can indirectly enhance synaptic vesicle cycling by improving calcium entry. However, care must be taken to avoid excitotoxicity.
V-ATPase Enhancers: Compounds that enhance V-ATPase function could improve vesicle acidification and neurotransmitter loading. This approach is in early preclinical development. [@peacock2024]
AAV-Delivered Synaptic Proteins: Viral vector delivery of SNAP-25, synaptotagmin, or other synaptic proteins to restore function. Early-phase clinical trials are exploring this approach.
RNA Interference: Targeting pathological proteins that impair synaptic function, such as alpha-synuclein, may restore synaptic vesicle cycling.
CRISPR-Based Approaches: Gene editing to correct disease-causing mutations in synaptic proteins is in development for familial forms of neurodegenerative diseases.
Alpha-Synuclein Aggregation Inhibitors: Reducing pathological alpha-synuclein species may protect synaptic vesicle function in PD.
Amyloid-Targeting Antibodies: While primarily aimed at plaques, anti-amyloid antibodies may also reduce soluble oligomers that impair synaptic function.
Tau-Reducing Therapies: Reducing tau pathology may restore presynaptic function in AD and tauopathies.
Synaptic vesicle proteins in cerebrospinal fluid serve as biomarkers:
These biomarkers may help identify patients early in disease progression and monitor treatment response.
Transgenic Models: APP/PS1 mice for AD, alpha-synuclein transgenic models for PD, SOD1 models for ALS
Electrophysiology: Whole-cell patch clamp, paired recordings, miniature excitatory postsynaptic current (mEPSC) analysis
Imaging: Super-resolution microscopy, live imaging of vesicle dynamics, electron microscopy of synaptic structures
This flowchart illustrates the synaptic vesicle cycling process and how amyloid-β oligomers disrupt this essential pathway, leading to synaptic dysfunction and cognitive decline.